目的　观察普米克气雾剂治疗儿童哮喘前后的最高呼气峰流速值 (PEF)及血清嗜酸细胞阳离子蛋白 (ECP)的变化。方法　对 113例儿童哮喘病人 ,使用普米克气雾剂 [(2 0 0～ 80 0 ) μg/d],3月～ 1年。采用峰流速仪监测PEF ,并用荧光免疫法 ,使用PharmaciaCAP系统 (瑞典 )测定部分病儿治疗前后的血清ECP。结果　使用普米克治疗后 ,PEF明显增高 ,3个月、6个月、1年的PEF占预计值的百分比 (PEF % )分别为 (93.6± 5 .4) ,(93.0± 4.2 ) ,(94.5± 4.5 ) ,与治疗前 (70 .4± 19.1)比较 ,差异有显著性 ,P <0 .0 1。治疗后ECP为 (7.5± 2 .7)μg/L ,比治疗前 (2 4.0± 17.1) μg/L明显下降 ,P <0 .0 1,差异有显著性。结论　普米克气雾剂治疗儿童哮喘副作用小、安全有效、方法简便 ,用于儿童哮喘的中、长期防治 ,值得推广。

Objective To observe the differences of peak expiratory flow (PEF), and serum eosinophil cationic protein (ECP) before and after Pulmicort aerosol inhalation for childhood asthma. Methods 113 asthmatic children treated with Pulmicort aerosol [(200～800) μg/d] for (3～12) months were studied. PEF was monitored with a peak flowmeter, and ECP was measured using fluoroimmunoassay (Pharmacia CAP system) before and after the treatment. Results PEF remarkably increased after inhalation therapy. Its percentage accounting for anticipant value after 3 m, 6 m, and 1 year ( 93.6 ± 5.4 , 93.0 ± 4.2 , 94.5 ± 4.5 ) had statistical significance compared with the percentage before inhalation therapy ( 70.4 ± 19.1 ) (P< 0.01 ). Serum ECP after the treatment [( 7.5 ± 2.7 ) μg/L] was significantly lower compared with ECP prior to inhalation [( 24.0 ± 17.1 ) μg/L] (P< 0.01 ). Conclusions Pulmicort aerosol appears to be an effective middle- and long-term therapy to treat and prevent childhood asthma because of its low incidence of side effects, its safety, and simplicity of use.